EUVIMEDEUVIMED entdecken
Crossref

Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis

Lawrence F Eichenfield, Jonathan I Silverberg, Adelaide A Hebert, Raj Chovatiya, Philip M Brown, Kimberly A McHale, David S Rubenstein, Anna M Tallman

Journal of Drugs in Dermatology · 2024

DOI: 10.36849/jdd.8026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Drugs in Dermatology, 2024. Verfasst von Lawrence F Eichenfield und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Stilbenes. Die Arbeit wurde bisher 8-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) is a chronic relapsing–remitting disease with a multifactorial etiology involving epidermal barrier and immunologic dysfunction. Topical therapies form the mainstay of AD treatment, but options are limited by adverse effects and restrictions on application site, duration, and extent of use. Tapinarof (VTAMA; Dermavant Sciences, Inc.) is a first-in-class, non-steroidal, topical aryl hydrocarbon receptor (AhR) agonist approved for the treatment of plaque psoriasis. AhR is a ligand-dependent transcription factor with wide-ranging roles, including regulation of homeostasis and immune response in skin cells. AhR expression and signaling are altered in many inflammatory skin diseases, and clinical trials with tapinarof have validated AhR as a therapeutic target capable of delivering significant efficacy. Tapinarof cream 1% once daily demonstrated efficacy versus vehicle in adults and adolescents with AD and is being investigated in the ADORING trials for the treatment of AD in adults and children down to 2 years of age. J Drugs Dermatol. 2024;23(2):23-28. doi:10.36849/JDD.8026.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicStilbenesHumansReceptors, Aryl HydrocarbonResorcinolsSkin

Substanzen

Receptors, Aryl HydrocarbonResorcinolsStilbenestapinarof

Zitieren

APA

Eichenfield, L. F., Silverberg, J. I., Hebert, A. A., Chovatiya, R., Brown, P. M., McHale, K. A., Rubenstein, D. S., & Tallman, A. M. (2024). Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.8026

Vancouver

Eichenfield LF, Silverberg JI, Hebert AA, Chovatiya R, Brown PM, McHale KA, et al. Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.8026

BibTeX
@article{Eichenfield2024,
  author = {Eichenfield, Lawrence F and Silverberg, Jonathan I and Hebert, Adelaide A and Chovatiya, Raj and Brown, Philip M and McHale, Kimberly A and Rubenstein, David S and Tallman, Anna M},
  title = {Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis},
  journal = {Journal of Drugs in Dermatology},
  year = {2024},
  doi = {10.36849/jdd.8026}
}
Kostenlos starten →